AACR19: pembrolizumab demonstrates promise in small-cell lung cancer patients

Keytruda® (pembrolizumab) has demonstrated promising anti-tumor activity in patients with pretreated, advanced-small cell lung cancer (SCLC) according to pooled analysis data from the Phase IB KEYNOTE-028 trial and the Phase II KEYNOTE-158 trial. The findings were recently presented at the AACR Annual Meeting (29 March–3 April, GA, USA).“Our study shows that pembrolizumab monotherapy can provide durable clinical benefit with manageable toxicity in this hard-to-treat patient population.”“Up to 70% of patients with SCLC have advanced disease at diagnosis,” explained Hyun Cheol Chung, Yonsei University College of Medicine (Seoul, Republic of Korea). “Current treatment guidelines specify a variety of first-and second-line treatment...